increased solubility = different PK profile? [Dissolution / BCS / IVIVC]

posted by Ohlbe – France, 2017-06-08 20:23 (2840 d 04:25 ago) – Posting: # 17469
Views: 14,939

Dear Dr Dan,

❝ The idea behind this question is to develop an oral formulation with a less drug load than the reference product but with the same bioavailability in order to decrease non-systemic adverse events.


There is one (old) example I can think of: fenofibrate. Very low solubility. Started with a 300 mg capsule formulation. Decreased to 200 mg with an improved formulation (if I remember correctly, co-micronisation with sodium laurylsulfate). Decreased further with new formulation improvements: 160 mg and now 145 mg tablets.

I don't know through which type of procedure they were approved, whether BE was demonstrated on both Cmax and AUC, and whether they did any clinical trials in addition to BE. But it may be worth having a look at public assessment reports, if available.
—
Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,669 registered users;
20 visitors (0 registered, 20 guests [including 9 identified bots]).
Forum time: 23:49 CET (Europe/Vienna)

I have not failed 700 times. I have not failed once.
I have succeeded in proving
that those 700 ways will not work.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5